-
1
-
-
1642544603
-
Focus on hepatocellular carcinoma
-
DOI 10.1016/S1535-6108(04)00058-3, PII S1535610804000583
-
J. Bruix, L. Boix, M. Sala, and J.M. Llovet Focus on hepatocellular carcinoma Cancer Cell 5 2004 215 219 (Pubitemid 38402113)
-
(2004)
Cancer Cell
, vol.5
, Issue.3
, pp. 215-219
-
-
Bruix, J.1
Boix, L.2
Sala, M.3
Llovet, J.M.4
-
2
-
-
83155175343
-
Clinical characteristics of patients with hepatocellular carcinoma in Austria - Is there a need for a structured screening program?
-
F. Hucke, W. Sieghart, M. Schöniger-Hekele, M. Peck-Radosavljevic, and C. Müller Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program? Wien. Klin. Wochenschr. 123 2011 542 551
-
(2011)
Wien. Klin. Wochenschr.
, vol.123
, pp. 542-551
-
-
Hucke, F.1
Sieghart, W.2
Schöniger-Hekele, M.3
Peck-Radosavljevic, M.4
Müller, C.5
-
3
-
-
7044286234
-
Introduction: The burden of hepatocellular carcinoma
-
L.B. Seeff Introduction: the burden of hepatocellular carcinoma Gastroenterology 127 2004 S1 S4
-
(2004)
Gastroenterology
, vol.127
-
-
Seeff, L.B.1
-
4
-
-
55749088393
-
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
-
S.M. Wilhelm, L. Adnane, P. Newell, A. Villanueva, J.M. Llovet, and M. Lynch Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling Mol Cancer Ther 7 2008 3129 3140
-
(2008)
Mol Cancer Ther
, vol.7
, pp. 3129-3140
-
-
Wilhelm, S.M.1
Adnane, L.2
Newell, P.3
Villanueva, A.4
Llovet, J.M.5
Lynch, M.6
-
5
-
-
33846212284
-
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
-
DOI 10.1158/0008-5472.CAN-06-1377
-
L. Liu, Y. Cao, C. Chen, X. Zhang, A. McNabola, and D. Wilkie Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 Cancer Res 66 2006 11851 11858 (Pubitemid 46094197)
-
(2006)
Cancer Research
, vol.66
, Issue.24
, pp. 11851-11858
-
-
Liu, L.1
Cao, Y.2
Chen, C.3
Zhang, X.4
McNabola, A.5
Wilkie, D.6
Wilhelm, S.7
Lynch, M.8
Carter, C.9
-
6
-
-
47949116252
-
Sorafenib in advanced hepatocellular carcinoma
-
J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.-F. Blanc Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
-
(2008)
N Engl J Med
, vol.359
, pp. 378-390
-
-
Llovet, J.M.1
Ricci, S.2
Mazzaferro, V.3
Hilgard, P.4
Gane, E.5
Blanc, J.-F.6
-
7
-
-
33846625146
-
COX-2 expression in hepatocellular carcinoma is an initiation event; while EGF receptor expression with downstream pathway activation is a prognostic predictor of survival
-
DOI 10.1245/s10434-006-9123-8
-
J. Foster, J. Black, C. LeVea, T. Khoury, B. Kuvshinoff, and M. Javle COX-2 Expression in hepatocellular carcinoma is an initiation event; while EGF receptor expression with downstream pathway activation is a prognostic predictor of survival Ann Surg Oncol 14 2007 752 758 (Pubitemid 46175323)
-
(2007)
Annals of Surgical Oncology
, vol.14
, Issue.2
, pp. 752-758
-
-
Foster, J.1
Black, J.2
LeVea, C.3
Khoury, T.4
Kuvshinoff, B.5
Javle, M.6
Gibbs, J.F.7
-
8
-
-
40449113855
-
Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma
-
DOI 10.1309/WF10QAAED3PP93BH
-
A.F. Buckley, L.J. Burgart, V. Sahai, and S. Kakar Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma Am J Clin Pathol 129 2008 245 251 (Pubitemid 352029315)
-
(2008)
American Journal of Clinical Pathology
, vol.129
, Issue.2
, pp. 245-251
-
-
Buckley, A.F.1
Burgart, L.J.2
Sahai, V.3
Kakar, S.4
-
9
-
-
38049059334
-
Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis
-
K.K. Tanabe, A. Lemoine, D.M. Finkelstein, H. Kawasaki, T. Fujii, and R.T. Chung Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis JAMA 299 2008 53 60
-
(2008)
JAMA
, vol.299
, pp. 53-60
-
-
Tanabe, K.K.1
Lemoine, A.2
Finkelstein, D.M.3
Kawasaki, H.4
Fujii, T.5
Chung, R.T.6
-
10
-
-
33748627437
-
Expression of betacellulin and epidermal growth factor receptor in hepatocellular carcinoma: Implications for angiogenesis
-
M. Woo Sung, P. Ho Sung, Y. Ki Hoon, P. MinYoung, K. Kyung Ryoul, and J. Kyu Yun Expression of betacellulin and epidermal growth factor receptor in hepatocellular carcinoma: implications for angiogenesis Hum Pathol 37 2006 1324 1332
-
(2006)
Hum Pathol
, vol.37
, pp. 1324-1332
-
-
Woo Sung, M.1
Ho Sung, P.2
Ki Hoon, Y.3
Minyoung, P.4
Kyung Ryoul, K.5
Kyu Yun, J.6
-
11
-
-
40849147041
-
EGFR antagonists in cancer treatment
-
F. Ciardiello, and G. Tortora EGFR antagonists in cancer treatment N Engl J Med 358 2008 1160 1174
-
(2008)
N Engl J Med
, vol.358
, pp. 1160-1174
-
-
Ciardiello, F.1
Tortora, G.2
-
12
-
-
24344489502
-
Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics
-
DOI 10.1016/j.jhep.2005.02.040, PII S0168827805002771
-
A. Huether, M. Hopfner, A.P. Sutter, D. Schuppan, and H. Scherubl Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics J Hepatol 43 2005 661 669 (Pubitemid 41253234)
-
(2005)
Journal of Hepatology
, vol.43
, Issue.4
, pp. 661-669
-
-
Huether, A.1
Hopfner, M.2
Sutter, A.P.3
Schuppan, D.4
Scherubl, H.5
-
13
-
-
27244447373
-
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer
-
DOI 10.1200/JCO.2005.14.696
-
P.A. Philip, M.R. Mahoney, C. Allmer, J. Thomas, H.C. Pitot, and G. Kim Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer J Clin Oncol 23 2005 6657 6663 (Pubitemid 46190260)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.27
, pp. 6657-6663
-
-
Philip, P.A.1
Mahoney, M.R.2
Allmer, C.3
Thomas, J.4
Pitot, H.C.5
Kim, G.6
Donehower, R.C.7
Fitch, T.8
Picus, J.9
Erlichman, C.10
-
14
-
-
34548150925
-
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma
-
DOI 10.1002/cncr.22886
-
M.B. Thomas, R. Chadha, K. Glover, X. Wang, J. Morris, and T. Brown Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma Cancer 110 2007 1059 1067 (Pubitemid 47312872)
-
(2007)
Cancer
, vol.110
, Issue.5
, pp. 1059-1067
-
-
Thomas, M.B.1
Chadha, R.2
Glover, K.3
Wang, X.4
Morris, J.5
Brown, T.6
Rashid, A.7
Dancey, J.8
Abbruzzese, J.L.9
-
15
-
-
34047118033
-
Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma
-
DOI 10.1016/j.jhep.2006.11.021, PII S0168827807000025
-
D. Semela, A.-C. Piguet, M. Kolev, K. Schmitter, R. Hlushchuk, and V. Djonov Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma J Hepatol 46 2007 840 848 (Pubitemid 46529039)
-
(2007)
Journal of Hepatology
, vol.46
, Issue.5
, pp. 840-848
-
-
Semela, D.1
Piguet, A.-C.2
Kolev, M.3
Schmitter, K.4
Hlushchuk, R.5
Djonov, V.6
Stoupis, C.7
Dufour, J.-F.8
-
16
-
-
0035398631
-
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
-
M. Hidalgo, L.L. Siu, J. Nemunaitis, J. Rizzo, L.A. Hammond, and C. Takimoto Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies J Clin Oncol 19 2001 3267 3279 (Pubitemid 32591445)
-
(2001)
Journal of Clinical Oncology
, vol.19
, Issue.13
, pp. 3267-3279
-
-
Hidalgo, M.1
Siu, L.L.2
Nemunaitis, J.3
Rizzo, J.4
Hammond, L.A.5
Takimoto, C.6
Eckhardt, S.G.7
Tolcher, A.8
Britten, C.D.9
Denis, L.10
Ferrante, K.11
Von Hoff, D.D.12
Silberman, S.13
Rowinsky, E.K.14
-
17
-
-
11244302427
-
Dietary lipid hydroperoxides induce expression of vascular endothelial growth factor (VEGF) in human colorectal tumor cells
-
DOI 10.1096/fj.04-2111fje
-
D. Jurek, N. Udilova, A. Jozkowicz, H. Nohl, B. Marian, and R. Schulte-Hermann Dietary lipid hydroperoxides induce expression of vascular endothelial growth factor (VEGF) in human colorectal tumor cells FASEB J 19 2005 97 99 (Pubitemid 40069930)
-
(2005)
FASEB Journal
, vol.19
, Issue.1
, pp. 97-99
-
-
Jurek, D.1
Udilova, N.2
Jozkowicz, A.3
Nohl, H.4
Marian, B.5
Schulte-Hermann, R.6
-
18
-
-
28844437366
-
Mcl-1 overexpression in hepatocellular carcinoma: A potential target for antisense therapy
-
DOI 10.1016/j.jhep.2005.09.010, PII S0168827805006227
-
W. Sieghart, D. Losert, S. Strommer, D. Cejka, K. Schmid, and S. Rasoul-Rockenschaub Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy J Hepatol 44 2006 151 157 (Pubitemid 41772529)
-
(2006)
Journal of Hepatology
, vol.44
, Issue.1
, pp. 151-157
-
-
Sieghart, W.1
Losert, D.2
Strommer, S.3
Cejka, D.4
Schmid, K.5
Rasoul-Rockenschaub, S.6
Bodingbauer, M.7
Crevenna, R.8
Monia, B.P.9
Peck-Radosavljevic, M.10
Wacheck, V.11
-
19
-
-
70349755366
-
Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats
-
T. Reiberger, B. Angermayr, P. Schwabl, N. Rohr-Udilova, M. Mitterhauser, and A. Gangl Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats J Hepatol 51 2009 865 873
-
(2009)
J Hepatol
, vol.51
, pp. 865-873
-
-
Reiberger, T.1
Angermayr, B.2
Schwabl, P.3
Rohr-Udilova, N.4
Mitterhauser, M.5
Gangl, A.6
-
20
-
-
77949322163
-
Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab
-
G.W. Prager, E.-M. Lackner, M.-T. Krauth, M. Unseld, M. Poettler, and S. Laffer Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab Mol Oncol 4 2010 150 160
-
(2010)
Mol Oncol
, vol.4
, pp. 150-160
-
-
Prager, G.W.1
Lackner, E.-M.2
Krauth, M.-T.3
Unseld, M.4
Poettler, M.5
Laffer, S.6
-
21
-
-
44649105082
-
Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma
-
A.-C. Piguet, D. Semela, A. Keogh, L. Wilkens, D. Stroka, and C. Stoupis Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma J Hepatol 49 2008 78 87
-
(2008)
J Hepatol
, vol.49
, pp. 78-87
-
-
Piguet, A.-C.1
Semela, D.2
Keogh, A.3
Wilkens, L.4
Stroka, D.5
Stoupis, C.6
-
22
-
-
57749189578
-
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial
-
A.-L. Cheng, Y.-K. Kang, Z. Chen, C.-J. Tsao, S. Qin, and J.S. Kim Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34
-
(2009)
Lancet Oncol
, vol.10
, pp. 25-34
-
-
Cheng, A.-L.1
Kang, Y.-K.2
Chen, Z.3
Tsao, C.-J.4
Qin, S.5
Kim, J.S.6
-
23
-
-
44449085884
-
Design and endpoints of clinical trials in hepatocellular carcinoma
-
J.M. Llovet, A.M. Di Bisceglie, J. Bruix, B.S. Kramer, R. Lencioni, and A.X. Zhu Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 2008 698 711
-
(2008)
J Natl Cancer Inst
, vol.100
, pp. 698-711
-
-
Llovet, J.M.1
Di Bisceglie, A.M.2
Bruix, J.3
Kramer, B.S.4
Lencioni, R.5
Zhu, A.X.6
-
24
-
-
36749052895
-
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
-
DOI 10.1073/pnas.0708148104
-
J.M.L. Ebos, C.R. Lee, J.G. Christensen, A.J. Mutsaers, and R.S. Kerbel Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy Proc Natl Acad Sci 104 2007 17069 17074 (Pubitemid 350210993)
-
(2007)
Proceedings of the National Academy of Sciences of the United States of America
, vol.104
, Issue.43
, pp. 17069-17074
-
-
Ebos, J.M.L.1
Lee, C.R.2
Christensen, J.G.3
Mutsaers, A.J.4
Kerbel, R.S.5
-
25
-
-
74249092481
-
Biomarkers of angiogenesis and their role in the development of VEGF inhibitors
-
N. Murukesh, C. Dive, and G.C. Jayson Biomarkers of angiogenesis and their role in the development of VEGF inhibitors Br J Cancer 102 2009 8 18
-
(2009)
Br J Cancer
, vol.102
, pp. 8-18
-
-
Murukesh, N.1
Dive, C.2
Jayson, G.C.3
-
26
-
-
46449091500
-
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma
-
A.B. Siegel, E.I. Cohen, A. Ocean, D. Lehrer, A. Goldenberg, and J.J. Knox Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma J Clin Oncol 26 2008 2992 2998
-
(2008)
J Clin Oncol
, vol.26
, pp. 2992-2998
-
-
Siegel, A.B.1
Cohen, E.I.2
Ocean, A.3
Lehrer, D.4
Goldenberg, A.5
Knox, J.J.6
-
27
-
-
0035132143
-
Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: A prospective study
-
DOI 10.1097/00000658-200102000-00012
-
R.T.-P. Poon, I.O.-L. Ng, C. Lau, L.-X. Zhu, W.-C. Yu, and C.-M. Lo Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study Ann Surg 233 2001 227 235 (Pubitemid 32106077)
-
(2001)
Annals of Surgery
, vol.233
, Issue.2
, pp. 227-235
-
-
Poon, R.T.-P.1
Ng, I.O.-L.2
Lau, C.3
Zhu, L.-X.4
Yu, W.-C.5
Lo, C.-M.6
Fan, S.-T.7
Wong, J.8
-
28
-
-
34249900712
-
High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: Importance of tumor biomarker in ablative therapies
-
DOI 10.1245/s10434-007-9366-z
-
R. Poon, C. Lau, R. Pang, K. Ng, J. Yuen, and S. Fan High Serum Vascular Endothelial Growth Factor Levels Predict Poor Prognosis after Radiofrequency Ablation of Hepatocellular Carcinoma: Importance of Tumor Biomarker in Ablative Therapies Ann Surg Oncol 14 2007 1835 1845 (Pubitemid 46870942)
-
(2007)
Annals of Surgical Oncology
, vol.14
, Issue.6
, pp. 1835-1845
-
-
Poon, R.T.P.1
Lau, C.2
Pang, R.3
Ng, K.K.4
Yuen, J.5
Fan, S.T.6
-
29
-
-
4644289324
-
Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level
-
X. Li, G.S. Feng, C.S. Zheng, C.K. Zhuo, and X. Liu Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level World J Gastroenterol 10 2004 2878 2882 (Pubitemid 39303010)
-
(2004)
World Journal of Gastroenterology
, vol.10
, Issue.19
, pp. 2878-2882
-
-
Li, X.1
Feng, G.-S.2
Zheng, C.-S.3
Zhuo, C.-K.4
Liu, X.5
-
30
-
-
41949113329
-
TTranscatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): The role of angiogenesis and invasiveness
-
DOI 10.1111/j.1572-0241.2007.01712.x
-
A. Sergio, C. Cristofori, R. Cardin, G. Pivetta, R. Ragazzi, and A. Baldan Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness Am J Gastroenterol 103 2008 914 921 (Pubitemid 351506379)
-
(2008)
American Journal of Gastroenterology
, vol.103
, Issue.4
, pp. 914-921
-
-
Sergio, A.1
Cristofori, C.2
Cardin, R.3
Pivetta, G.4
Ragazzi, R.5
Baldan, A.6
Girardi, L.7
Cillo, U.8
Burra, P.9
Giacomin, A.10
Farinati, F.11
-
31
-
-
0141679409
-
Laminin-5 chains are expressed differentially in metastatic and nonmetastatic hepatocellular carcinoma
-
G. Giannelli, E. Fransvea, C. Bergamini, F. Marinosci, and S. Antonaci Laminin-5 chains are expressed differentially in metastatic and nonmetastatic hepatocellular carcinoma Clin Cancer Res 9 2003 3684 3691 (Pubitemid 37169236)
-
(2003)
Clinical Cancer Research
, vol.9
, Issue.10
, pp. 3684-3691
-
-
Giannelli, G.1
Fransvea, E.2
Bergamini, C.3
Marinosci, F.4
Antonaci, S.5
-
32
-
-
11244275453
-
Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells
-
DOI 10.1038/sj.bjc.6602231
-
G. Giannelli, A. Azzariti, E. Fransvea, L. Porcelli, S. Antonaci, and A. Paradiso Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells Br J Cancer 91 2004 1964 1969 (Pubitemid 40065526)
-
(2004)
British Journal of Cancer
, vol.91
, Issue.11
, pp. 1964-1969
-
-
Giannelli, G.1
Azzariti, A.2
Fransvea, E.3
Porcelli, L.4
Antonaci, S.5
Paradiso, A.6
|